Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine

  • Authors:
    • Zhongqiang Guo
    • Xiaoyu Zhang
    • Xuesong Li
    • Feng Xie
    • Boxing Su
    • Min Zhang
    • Liqun Zhou
  • View Affiliations

  • Published online on: December 23, 2014     https://doi.org/10.3892/or.2014.3696
  • Pages: 1519-1525
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate cancer is a leading cause of cancer-related death among men. Early diagnosis and treatment are successful against prostate cancer, yet the clinical treatment of advanced prostate cancer remains a challenge. Gemcitabine is used to treat a broad spectrum of solid tumors; however, the clinical response of prostate cancer patients to gemcitabine is limited. In the present study, we showed that HMGN5, a nucleosome binding protein that can unfold chromatin by binding to histone (H1), is overexpressed in prostate cancer cells and plays an oncogenic role in prostate cancer tumorigenesis and development by activating the MAPK signaling pathway. We also found that sensitivity of prostate cancer cells to gemcitabine was positively correlated with HMGN5 expression. Knockdown of HMGN5 expression reduced the sensitivity of PC-3 cells to gemcitabine, and ectopic HMGN5 expression in DU145 cells enhanced the sensitivity to gemcitabine. Gemcitabine decreased HMGN5 expression, consequently leading to inactivation of the MAPK signaling pathway and cleavage of the PARP protein. Finally, we showed that PC-3 cells acquire gemcitabine resistance by gradual loss of HMGN5 expression. The present study suggests that HMGN5 is a potential biomarker for treating prostate cancer, and patients with a high level HMGN5 will benefit from gemcitabine treatment.
View Figures
View References

Related Articles

Journal Cover

March-2015
Volume 33 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Guo Z, Zhang X, Li X, Xie F, Su B, Zhang M and Zhou L: Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine. Oncol Rep 33: 1519-1525, 2015
APA
Guo, Z., Zhang, X., Li, X., Xie, F., Su, B., Zhang, M., & Zhou, L. (2015). Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine. Oncology Reports, 33, 1519-1525. https://doi.org/10.3892/or.2014.3696
MLA
Guo, Z., Zhang, X., Li, X., Xie, F., Su, B., Zhang, M., Zhou, L."Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine". Oncology Reports 33.3 (2015): 1519-1525.
Chicago
Guo, Z., Zhang, X., Li, X., Xie, F., Su, B., Zhang, M., Zhou, L."Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine". Oncology Reports 33, no. 3 (2015): 1519-1525. https://doi.org/10.3892/or.2014.3696